CHART THE UNCHARTED
CREATING INNOVATION FOR PATIENTS
New Current
See all

June 17, 2025
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
Read MoreFeatured Creations
See all
Catalyzing Transpacific Partnership
The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an “on-the-ground”, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.
Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”
Nobuo Hanai, PhD